CATIE: Choice of antipsychotics in schizophrenia;CATIE: Die auswahl von antipsychotika bei schizophrenie

PsychoNeuro

Volumn 31, Issue 10, 2005, Pages 523-525

  Fritze, Jürgen ^a   Aldenhoff, Josef B ^a   Bergmann, Frank ^a   Maier, Wolfgang ^a   Möller, Hans Jürgen ^a  

^a Psychotherapie und Nervenheilkunde (DGPPN)   (Germany)

Author keywords

Atypical neuroleptics; CATIE; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADAPTATION; AVOIDANCE BEHAVIOR; COGNITION; DRUG CHOICE; DRUG EFFICACY; HUMAN; MEDICAL ASSESSMENT; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 27944492260     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922242     Document Type: Review

References (13)

1. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299
2. Awad AC, Voruganti LNP: New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability - Are Patients Better Off? Can J Psychiatry 2004; 49: 297-302
3. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13 Suppl 3:49-57
4. Fritze J. Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2004. Psychoneuro 2005; 31:46-52
5. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65: Suppl 9:21-24
6. Kane JM: Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 (Suppl 9): 16-20
7. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201-222
8. Lambert M, Naber D: Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004; 18: Suppl 2:5-17
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine 2005; 353:1209-1223
10. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005; 10:79-104
11. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002
12. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Click ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29:15-31
13. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429